Article
The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Pharmacological research - 1 Jul 2013
Shen Li, Peng Hongchun, Xu Danyan, Zhao Shuiping
Abstract excerpt
Proprotein convertase subtilisin/kexin 9 (PCSK9) has been shown to degrade hepatic low-density lipoprotein receptors (LDLR). Gain-of-function mutations promote the development of familial hypercholesterolemia, whereas loss-of-function mutations are associated with lower levels of circulating low-density lipoprotein cholesterol (LDL-C) and significant protection against coronary heart disease. The major classes of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.